Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
AssigneeBoard of Regents, The University of Texas System
InventorsCassian YEE, Ke PAN, Yulun CHIU
Life of this patent
Estimating the term…
Abstract
This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigens FANCI, RAD51, and PBK. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.
Claims262
A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:7 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:7.
A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:14 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:14.
A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:21 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:21.
A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:28 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:28.
A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:35 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:35.
A polypeptide comprising an antigen binding variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:42 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:42.
An engineered T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR3 with the amino acid sequence of SEQ ID NO:7 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:7;
- and the TCR-b polypeptide comprises a CDR3 with the amino acid sequence of SEQ ID NO:14 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:14.
An engineered T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR3 with the amino acid sequence of SEQ ID NO:21 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:21;
- and the TCR-b polypeptide comprises a CDR3 with the amino acid sequence of SEQ ID NO:28 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:28.
An engineered T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR3 with the amino acid sequence of SEQ ID NO:35 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:35;
- and the TCR-b polypeptide comprises a CDR3 with the amino acid sequence of SEQ ID NO:42 or an amino acid sequence with at least 80% sequence identity to SEQ ID NO:42.
A peptide comprising at least 55% sequence identity to a peptide of one of SEQ ID NOS:43-45.
Dependencies are inferred from the claim text.